New Technologies for Outcome Measures in Glaucoma: Review by the European Vision Institute Special Interest Focus Group

Ghislaine L. Traber\textsuperscript{a, b} Maria della Volpe-Waizel\textsuperscript{a, b} Peter Maloca\textsuperscript{b}

Ursula Schmidt-Erfurth\textsuperscript{c} Gary Rubin\textsuperscript{d} Botond Roska\textsuperscript{b} M. Francesca Cordeiro\textsuperscript{d–f}

Tilman Otto\textsuperscript{g} Richard Weleber\textsuperscript{h} Luis Andres Lesmes\textsuperscript{i} Angelo Arleo\textsuperscript{j}

Hendrik P.N. Scholl\textsuperscript{a, b}

\textsuperscript{a}Department of Ophthalmology, University Hospital Basel, University of Basel, Basel, Switzerland; \textsuperscript{b}Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland; \textsuperscript{c}Department of Ophthalmology, Medical University of Vienna, Vienna, Austria; \textsuperscript{d}Institute of Ophthalmology, UCL University College London, London, UK; \textsuperscript{e}Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UK; \textsuperscript{f}Imperial College Ophthalmic Research Group (ICORG), Imperial College London, London, UK; \textsuperscript{g}Heidelberg Engineering GmbH, Heidelberg, Germany; \textsuperscript{h}Casey Eye Institute, Departments of Ophthalmology and Molecular and Medical Genetics, University of Oregon Health & Science University, Portland, OR, USA; \textsuperscript{i}Adaptive Sensory Technology, Inc., San Diego, CA, USA; \textsuperscript{j}Institut de la Vision, CNRS, INSERM, Sorbonne Université, Paris, France

Keywords
Glaucoma · Retinal ganglion cell · Neurodegeneration · Outcome measure · Structure-function correlation

Abstract
Glaucoma is the leading cause of irreversible blindness worldwide, with an increasing prevalence. The complexity of the disease has been a major challenge in moving the field forward with regard to both pathophysiological insight and treatment. In this context, discussing possible outcome measures in glaucoma trials is of utmost importance and clinical relevance. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on “New Technologies for Outcome Measures in Retina and Glaucoma,” addressing both functional and structural outcomes, as well as translational hot topics in glaucoma and retina research. In conjunction with the published literature, this review summarizes the meeting focusing on glaucoma.

Introduction
Worldwide, glaucoma is the leading cause of irreversible blindness \cite{1}. The hallmark of the disease is the degeneration of retinal ganglion cells and their axons, resulting in progressive optic neuropathy with typical changes to the optic disc \cite{2, 3}. Glaucomatous neurodegeneration is related to the level of intraocular pressure, albeit also independent thereof, and even does not seem to be confined to the anterior visual pathway \cite{4}. Still, lowering intraocular pressure currently is the only proven therapeutic option \cite{2, 5}.

Given its age-related nature, this global epidemic is still on the rise, not only causing significant visual disability but also adding further to our health-economic burden \cite{6}. The complexity of the disease has been a major challenge in moving the field forward, both with regard to pathophysiological insight and treatment. Considering the slow progression of the disease, realization of glau-
coma trials is further hampered by their duration, required sample size, and resulting costs. In this context, a discussion of possible outcome measures is highly relevant in order to possibly clear these hurdles by improving the sensitivity of surrogate endpoints.

A recent meeting of the European Vision Institute (EVI) special interest focus group was held on “New Technologies for Outcome Measures in Retina and Glaucoma,” hosted by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), University of Basel, Switzerland, November 8–9, 2018.

The agenda with presentations of international clinicians and scientists was selected by Hendrik Scholl and the EVI steering committee. Backed up by published literature, the presentations and discussions are summarized below, focusing on glaucoma.

Presentation Summaries

**Active Learning for Precision Measurement of Visual Function**

With the idea of improving the precision of vision testing, Luis Andres Lesmes and coworkers from Adaptive Sensory Technology, Inc., introduced the concept of active learning, which improves the assessment of contrast sensitivity (CS) and visual acuity (VA) through the combination of digitized displays, novel quantitative Bayesian models of visual function, and intelligent sampling algorithms that personalize testing to each patient. For each patient, the active learning algorithm evaluates an expansive space of potential test outcomes, searches a large library of potential contrast and acuity test items, and converges them into a test sequence comprising optimal queries for each patient based on their previous responses.

The CS function (CSF) is fundamental to vision science, a threshold contour that represents the boundary between what one can see in the world and what one cannot (Fig. 1, left). Rather than estimate contrast sensitivities for individual spatial frequency conditions, the quick CSF (qCSF) directly estimates a Bayesian parameterization of the function’s global shape. Using the higher pixel and contrast resolution of digital displays, as well as an intelligent algorithm for sampling stimulus size and contrast, the qCSF algorithm presents the patient with the size-contrast combinations that comprise an optimal assessment of the personalized shape of the patient’s CSF (Fig. 1, right). The CSF shows disease-specific patterns of function loss in various ophthalmic conditions including glaucoma [7–13] and might thus serve as a valuable outcome measure by revealing hidden signals of early vision loss and by improving the statistical power for detecting visual changes through a better signal-to-noise ratio [14].

VA testing has typically implemented two complementary but exclusive strategies: (1) static, chart-based testing that presents optotypes of fixed sizes in rows (ETDRS and Pelli-Robson charts), or (2) computerized testing that applies a staircase to change the size of single optotypes [15]. Lesmes and Dorr [16] have proposed a quantitative VA (qVA) algorithm which combines these approaches to change the size of multiple optotypes, using a row-based psychometric function of expected correct optotypes as a function of logMAR optotype size. With intelligent sampling of optotype size (true 0.02-logMAR resolution), the algorithm reduces the noise in VA testing and provides fine-grained information on the threshold and range of the VA psychometric function.

The qCSF and qVA algorithms have exhibited potential to improve the statistical power for reliably detecting subtle but potentially clinically significant signals in visual function. Because the definition of a clinically meaningful change is constrained by what is clinically measurable, there is potential for novel methodology to drive the threshold of what is accepted both by clinicians and by regulatory authorities as clinically relevant.

**Microperimetry as a Visual Function Endpoint**

Gary Rubin’s talk focused on microperimetry. There are currently three different commercially available microperimeters. The NIDEK MP-3 (NIDEK Co. Ltd, Gamagori, Japan) and the MAIA (CenterVue, Padua, Italy) combine microperimetry with nonmydriatic color fundus imaging and scanning laser ophthalmoscopy (SLO) imaging, respectively. The OptosOCT SLO (Optos PLC, Dunfermline, UK) is the first device to superimpose microperimetry data on OCT images. Eye tracking allows the projection of stimuli onto different retinal locations with imaging of the fundus in real time. Microperimetry is thus providing structure-function correlations and is particularly useful in patients with unstable or eccentric fixation. The technology has mainly been applied in retinal diseases.

Gary Rubin comments on its use in the EFFECT (Eccentric Fixation from Enhanced Clinical Training) trial on recent-onset macular disease (Rubin G. First results from the EFFECT Trial, an RCT of eccentric viewing training for patients with AMD, ARVO Annual Meeting Abstract, June 2017, Baltimore, MD, USA, May 7–11, 2017. Invest Ophthalmol Vis Sci. 2017 Jun;58:4766) [17] and in gene therapy trials on Leber’s congenital amauro-
sis [18, 19]. However, microperimetry has also been investigated in glaucoma. The published literature highlights aspects of interest including a comparison with standard automated perimetry [20–22], structure-function correlations [22–26], assessment of early glaucoma detection [27], visual field evaluation in advanced glaucoma [28, 29], and fixation instability in glaucoma [30, 31].

**Modeling and Analysis of the Hill of Vision of Full-Field Static Perimetry**

On behalf of Richard Weleber, Hendrik Scholl explained the concept of visual field modeling and analysis (VFMA). The hill of vision (HOV) is a functional measure of the total light sensitivity across the retina, which VFMA visualizes via a color-coded 3D sensitivity surface. A single volumetric measure in decibel-steradian (dB-sr) units quantitatively estimates the HOV. As opposed to conventional visual field indices (e.g., mean sensitivity, mean defect, and square root of loss variance), VFMA not only captures the whole visual field sensitivity in one single endpoint (dB-sr), but also has a flexible region of interest and is more robust with regard to grid changes. The latter is explained by the fact that HOV computation is achieved by interpolated dense VFMA gridding based on sparse gridding of the measured raw data. As a consequence, the HOV volume is a flexible and robust measure of quantity resulting in a stronger, more focused endpoint.

The methodology was established in 2015 [32] and since then has been used in several trials including the RPE65 gene therapy trial [33]. VFMA mainly has been adopted in trials on retinal disease, but it could without doubt be established in glaucoma as well. Standard visual field testing frequently fails to detect early arcuate glaucomatous visual field loss in the central macula just superior to fixation [24]. Since the respective retinal ganglion cells of the inferior macula are particularly vulnerable to glaucomatous damage, additional screening of this area with condensed stimulus arrangements has been suggested. However, the utility of this approach still has to be substantiated, since grids of greater spatial density in re-
regions of interest do break the usefulness of the conventional visual field indices in their ability to compare to fields with standard grids.

Behavioral Outcome Measures and Naturalistic Testing

Angelo Arleo presented his group’s research on the visuospatial behavioral performance of young and older participants. The Streetlab reproduced a 10 × 5 portion of a street-like environment. It ensured visual immersion through realistic relief elements (imitating doors, windows, and brick walls), and audio immersion through a 3D multisource sound system. The floor was covered by a black linoleum surface and there were no obstacles. Light conditions were fully controlled by varying both intensity and temperature parameters. The subject’s whole body and eye movements were monitored through a set of biometric sensors: an optoelectronic Vicon motion capture system (10 infrared cameras, at a sampling frequency of 120 Hz) and a wearable eye tracking system (by MocapLab, at 60 Hz). Data from all sensors were synchronized and recorded in real time, allowing any kinematic recording to be replayed and analyzed offline. Adapted, with permission, from Streetlab©.

The ecological setup mentioned above with both a naturalistic and a virtual environment adds a completely new dimension to possible future outcome measures and also seems interesting in the context of glaucoma, since glaucoma not only appears to be restricted to retinal ganglion cell loss with subsequent visual field defects, but might also be associated with more widespread neurodegeneration.
**New Technologies for Outcome Measures in Glaucoma**

**Peter Maloca, MD**, presented his group’s hardware and software innovations in optical coherence tomography (OCT) imaging. HYDRA Dual Wavelength OCT (HydraOCT) is a dual coaxial OCT system with a second light source of 1,060 nm in addition to the existing 870-nm light source. The system is based on the Spectralis OCT system (Heidelberg Engineering, Heidelberg, Germany) and can be easily integrated into clinical routine. Maloca claims that HydraOCT allows better visualization of deeper retinal structures and provides additional information, since the refractive index can also be calculated due to the two different wavelengths, thus enabling direct tissue measurements. The portable MIMO OCT device implements a very fast so-called sparse OCT scanning system and was designed for self-monitoring of patients at home [37, 38]. The data are supposed to be analyzed with a cloud-based machine learning platform and are then displayed to patients or physicians for continuous monitoring of possible disease progression. At the same time, this would allow monitoring of large patient cohorts. The latter is applicable to both retinopathies and glaucoma.

With regard to software developments, Maloca presented their 3D speckle denoiser [39], which improves the signal-to-noise ratio not only for OCT imaging but also for 3D ultrasound, computed tomography, and possibly other imaging modalities [40–44]. This might allow a more accurate segmentation of retinal and optic nerve structures. Finally, the audience caught a glimpse of the technological potential of original 3D point cloud data being “injected” and instantly rendered into an interactive virtual reality environment [45]. The group has applied artificial intelligence (AI)-based segmentation of the data and allows the “virtual reality pilot” to interact with it. Ultimately, the virtual environment might allow the sharing of standardized mobility mazes between centers as outcome measures.

**Advancements in Diagnostic Imaging Modalities**

**Tilman Otto** from Heidelberg Engineering gave a comprehensive overview of advancements in diagnostic imaging modalities, a summary of which is clearly beyond the scope of this review. A more detailed summary is provided by della Volpe-Waizel et al. [66] in this issue of *Ophthalmic Research*. Basically, the imaging technologies either involve single- or two-photon interactions. Most imaging technologies are based on single-photon interactions, which include backscattering, as in conventional fundus photography, SLO, OCT, and OCT angiography imaging, and detection of fluorescence via biofluorescence or fluorescent dyes.

OCT elastography (OCE) is an imaging development that might be relevant to corneal pathologies or glaucoma. OCE allows OCT-based measurements of subtle structural fundus changes due to mechanical stress (e.g., increased intraocular pressure [IOP]) and derives information on tissue elasticity [46]. The development of the technology is at a preclinical stage. However, in the future it might shed light on pathophysiological mechanisms resulting from stress and strain on the ocular connective tissue. The latter is dependent on translamellar pressure, the anatomy of the optic nerve head, and mechanical stiffness. Regarding glaucoma trials, one might hypothesize that OCE may allow patient risk stratification for disease progression based on predisposing differences in mechanical properties of the ocular connective tissue.

**AI in Retinal Imaging**

Today, AI is omnipresent and ophthalmology is at its forefront. **Ursula Schmidt-Erfurth** outlined the tremendous development our field has experienced, starting out from conventional 2D fundus photography, having evolved into 3D OCT imaging of even subclinical pathologies over the last 25 years [47], and recently having moved into the era of deep learning since the early 2010s. The rudiments of AI have been available since the 1950s. However, only with the increase in data volume and server capacity came a considerably improved level of operation. Vice versa, the exponential rise in available imaging data has necessitated AI to identify and quantify relevant biomarkers by providing automated segmentation, quantification of lesions, pattern recognition, prediction of recurrence or progression, and structure-function correlation, amongst other features.

Sequential neuronal networks enable a deep learning system to identify clinical features the system has not been trained with before in a so-called black box manner [48]. Even though attention maps can highlight the anatomical regions the algorithm has taken into consideration (e.g., for determining gender) [49], the clinician might still not be able to fully retrace how a neural network has come to a particular conclusion, with obvious implications for data interpretation and reliability assessment [48]. While AI has predominantly been used in retinal diseases, it is also increasingly applied to fundus photography [50, 51], OCT [52], and visual field evaluation [53] for glaucoma, with the ultimate goal of early diagnosis, progression analysis, and overall risk stratification, which would allow appropriate therapeutic interventions [54].
Detection of Apoptosing Retinal Cells

*M. Francesca Cordeiro* presented the evolution of the DARC (detection of apoptosing retinal cells) technology from bench to bedside. ATP-dependent "flippases" normally maintain phosphatidylserine (PS) predominantly in the cytosolic leaflet of cell membranes [55]. However, under stress or during early apoptosis, PS flips to the cell surface. The DARC technology is based on the high affinity of intravenous fluorescently labelled annexin A5 to PS, which is exposed on the surface of cells under stress. Intravenous injection of ANX776 thus allows imaging of stressed or apoptosing retinal ganglion cells in glaucoma.

DARC has been investigated and established in multiple rodent studies. A recently published phase I clinical trial [56] allowed proof of concept in humans. DARC proved to be a safe method for monitoring RGC apoptosis, and there was a significant difference in DARC count between healthy controls and patients with progressing glaucoma. Late diagnosis and treatment, with subsequent visual loss, represent major challenges to the management of glaucoma patients, and research is hampered by a lack of clinically meaningful endpoints and by the long duration of clinical trials. In that context, the DARC count seems a promising early and objective clinical endpoint and might provide a new tool for testing the clinical efficacy of therapies for glaucoma and other neurodegenerative diseases [55].

Induced Pluripotent Cell Technology for in vitro Preclinical Testing

*Botond Roska* started out from a histological drawing of the retina by Cajal, the 1906 Nobel prize winner for his milestone work on the basic principles of organization of the nervous system. Cajal described different cell morphologies, concluding that the retina is a neural network of different cell types. Today we know that these cell types have unique gene expression patterns [57–59] and that most retinal diseases are cell type specific. While the architecture of the retina is very conserved across vertebrates, the gene expression pattern is different from species to species [57, 58]. For this reason, it appears to be difficult to develop a gene therapy in mice and translate it to humans.

Botond Roska’s group instead focuses on human retinal cells. On the one hand, the group uses organ donor retinal explants to study visual processing of the retina with microchips and to build a human gene expression library of the different cell types. On the other hand, the group has managed to grow retinal organoids in a dish from skin biopsies. These retinal organoids are structurally similar to normal retinas and have turned out to show an identical rate of development to that found in published data on fetal retinal development with a gene expression map convergence around 30 weeks of gestation.

Realizing that retinal ganglion cells would undergo early apoptosis without the connecting neuron in the brain, the group has been successful in growing eye-brain organoids. GFP (green fluorescent protein) virus vector labeling of ganglion cell axons allows visualization of the organoid’s optic nerve and its connections to the organoid’s brain, which represents an ideal in vitro model for glaucoma research. The organoid’s optic nerve can be exposed to pressure, hypoxia, or neurotrophic or neurotoxic substances to tackle neurodegeneration mechanisms in glaucoma. In addition, Botond Roska’s group has not only produced 230 viral vectors targeting many cell types in the retina [60] but has also developed so-called remote control viruses. These are superinfective viruses packed on the surface of magnetic beads which, once injected into the eye, can be guided and massaged onto the retinal surface by an external magnetic field for future optimized delivery of gene therapy to the target tissue [61].

---

Fig. 3. Detection of apoptosing retinal cells (DARC). Scanning laser ophthalmoscopy fundus image with an ICGA setting showing hyperfluorescent DARC spots (arrow) in a glaucoma patient. Fluorescently labelled ANX776 has a high affinity to phosphatidylserine, which is exposed on the surface of cells under stress. Intravenous injection of ANX776 thus allows imaging of stressed or apoptosing retinal ganglion cells in glaucoma.
Discussion and Conclusion

Reduction of IOP is known to slow glaucoma progression in terms of visual field or functional loss [62–64]. Thus, IOP and standard visual fields are the endpoints accepted by the Food and Drug Administration (FDA) in studies evaluating new therapies for glaucoma [65]. However, given the fact that glaucoma is a complex disease, alternative therapeutic targets are being investigated, entailing a need for new surrogate endpoints. For its potential to detect subtle changes in the neurodegenerative activity of disease, DARC may thus be applied in trials testing neuroprotective properties of drugs.

Structural parameters in the glaucoma literature typically include retinal nerve fiber layer, ganglion cell layer, and optic disc changes. However, structural endpoints are still not established for use in clinical trials for new glaucoma drugs, as long as the structural-functional relationship at different glaucoma stages remains insufficiently characterized [65]. In the meantime, structural endpoints still may have a role in proof-of-concept studies. In addition, it is conceivable that a combination of functional and structural endpoints will accelerate translational approaches, reduce the duration and cost of clinical trials, and thus improve visual health in the future. OCE clearly is on an exploratory level. However, the other presented refined technologies of imaging, visual function assessment, and data analysis may allow a better characterization of structure-function correlations, which is pivotal to improve study designs in the future.

The EVI special interest focus group joined forces to contribute to this long-term ambition by addressing both functional and structural measures as well as translational hot topics in glaucoma and retina research. This meeting impressively illustrated the ongoing scientific and technological progress in our field, exploring every magnitude in time and space—from picoseconds to long-term follow-up, from electrons to eye-brain organoids, and from subclinical to augmented reality. With this ever-increasing amount of information available from a single subject, it seems natural that more sophisticated, AI-based analysis and visualization of data becomes indispensable. This in turn is dependent on big data from collaborative projects, which clearly is the vision of the EVI.

Acknowledgements

The symposium thanks the EVI for support and organization, all the speakers, and the attendees at the meeting.

Statement of Ethics

The authors have no ethical conflicts to disclose.

Disclosure Statement

M. della Volpe-Waizel received consultation fees from Novartis; P. Maloca is owner of intellectual property on speckle noise analysis and the MIMO OCT discussed in the manuscript and received lecture fees from Heidelberg Engineering® GmbH and Zeiss; U. Schmidt-Erfurth declares to be a consultant for Novartis, Genentech, Boehringer, and Roche; G. Rubin declares that he is a consultant for Pixium Vision SA and MeiraGTx; M.F. Cordeiro is a named inventor on patents for DARC technology, currently owned by UCL, and is Director of Illustratum Ltd.; T. Otto declares to be Head of Technology Management – Ophthalmic Devices at Heidelberg Engineering® GmbH. R. Weleber declares the following conflicts of interest: Foundation Fighting Blindness: Vice-Chair for Scientific Advisory Board (SAB), Member of Executive Scientific Advisory Board (ESAB) (honorarium received); AGTC-SAB, Co-Investigator for three trials: RPE65 LCA, XLRS1, and CNGB3 ACHR; Consultant (Past): Oxford-Biomedica, Pfizer, and Novartis; Consultant (Current): NightStaRx, QLT, and 4D Molecular Therapeutics; Sanofi: Past PI and now Co-Investigator for two clinical treatment trials: USHSTAT and STARGEN; Holder of US Patent No. 8657446 Visual Field Modeling and Analysis (VFMA). A subset of his presentation material was given at a NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Disease held at the NEI in November 2016 [67]. L.A. Lesmes discloses financial, intellectual property, and employment interests in Adaptive Sensory Technology, Inc., which is commercializing novel devices for acuity and CS testing; A. Arleo declares to be the Head of the Essilor-ANR SilverSight Chair and to be a consultant for Essilor. H.P.N. Scholl declares the following conflicts of interest: Data Monitoring Committee: Genentech Inc./F. Hoffmann-La Roche Ltd (CHROMA and SPECTRI trials), Genzyme Corp./Sanofi, and ReNeuron Group Plc/Ora Inc.; Steering Committee: Novo Nordisk (FOCUS trial); Scientific Advisory Board: Astellas Institute for Regenerative Medicine, Gensight Biologics, Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Re-Neuron Group Plc/Ora Inc., Pharma Research & Early Development (pRED) of F. Hoffmann-La Roche Ltd, and Vision Medicines, Inc.; Consultancy: Boehringer Ingelheim Pharma GmbH & Co. KG, Daichi Sankyo, Inc., Gerson Lehrman Group, Guidepoint, and Shire; and Co-Director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB), which is constituted as a nonprofit foundation and receives funding from the University of Basel, the University Hospital Basel, Novartis, and the government of Basel-Stadt.

Except as noted above, all authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; and membership, employment, consultancies, stock ownership, or other equity interest; or any expert testimony or patent-licensing arrangements) or nonfinancial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.
Funding Sources

H.P.N. Scholl was supported by an unrestricted grant from Acucela Inc., Aegerion Pharmaceuticals (Novelion Therapeutics), Kinarus AG; NightstaRx Ltd., Ophthotech Corporation, and Spark Therapeutics England, Ltd.; M. della Volpe-Waizel was supported by an unrestricted grant from the SAMW (Schweizerische Akademie der Medizinischen Wissenschaften), SNF (Swiss National Science Foundation), and Bangerter Foundation.

Author Contributions

All authors wrote the manuscript, took part in the revision process, and approved the final submission.

References


